Clinical Trials on Bladder Urothelial Carcinoma In Situ

Total 21726 results

Liao Ning

Recruiting

Intra-operative Radiotherapy For Women With Ductal Carcinoma in Situ Breast Cancer

Breast Neoplasms

China
Hellenic Cooperative Oncology Group

Completed

Prognostic Biomarkers in Patients With Urothelial Carcinoma

Bladder Cancer
UroGen Pharma Ltd.

Recruiting

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto (uTRACT)

Carcinoma, Transitional Cell | Urothelial Carcinoma | Urothelial Cancer of Renal Pelvis | Urothelial Carcinoma Ureter | Urothelial Carcinoma Recurrent | Urothelial Carcinoma of the Renal Pelvis and Ureter | Urothelial Carcinoma Ureter Recurrent | Transitional Cell Carcinoma of Renal Pelvis

United States
Incyte Corporation

Terminated

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Metastatic Urothelial Carcinoma | Unresectable Urothelial Carcinoma

Spain, France, United States, Italy, Japan, Ireland, Slovakia, Austria, Belgium, Canada, Finland, Germany, Poland, Portugal, Romania, United Kingdom
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

Breast Ductal Carcinoma In Situ

United States, Canada, Puerto Rico, Korea, Republic of
Theodor Bilharz Research Institute

Recruiting

Microbiota in Urine and Urothelium Can be a Factor for Induction of Urinary Bladder Cancer. The Study Will Examine Urine and Bladder Tissues From Egyptian Male Patients and Controls Using Whole Genomic Sequencing Techniques and 16S rRNA. The Aim is to Elucidate Role of Microbiota in Bladder Cancer. (Cancer bladder)

Microbiota in Patients With Urinary Bladder Carcinoma in Urine and Cancer Tissues

Egypt
Uppsala University
Royal Marsden NHS Foundation Trust; Uppsala University Hospital; Westmead Breast... and other collaborators

Recruiting

Oncologic, Cosmetic and Patient Reported Outcomes in Value-Based Breast Surgery (OnCoPRO Value) (OncoPROValue-1)

Breast Cancer | Breast Carcinoma in Situ | Breast Cancer Invasive | Breast Asymmetry

United Kingdom, Sweden, Australia
Memorial Sloan Kettering Cancer Center
New York University; Novartis Pharmaceuticals; University of Hawaii

Completed

RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder

Bladder Cancer

United States
Infinity Pharmaceuticals, Inc.
Bristol-Myers Squibb

Completed

Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)

Solid Tumor | Bladder Cancer | Advanced Cancer | Urothelial Carcinoma

France, Spain, United States, Italy, Czechia, Poland, Serbia
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer

Ductal Breast Carcinoma in Situ | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier | Atypical Ductal Breast Hyperplasia | Lobular Breast Carcinoma in Situ

United States
Eli Avisar

Withdrawn

Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors

Breast Cancer | Invasive Breast Carcinoma | Ductal Carcinoma In-situ
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Oxybutynin Chloride in Managing Hot Flashes

Hot Flashes | Breast Carcinoma | Lobular Breast Carcinoma In Situ | Ductal Breast Carcinoma In Situ | No Evidence of Disease

United States
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer

Metastatic Urothelial Carcinoma | Locally Advanced Urothelial Cancer

China
Pacific Edge Limited

Recruiting

CxBladder Surveillance of Intermediate and High-Risk Bladder Cancer Patients

Urothelial Bladder Cancer

United States
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4)

Urinary Bladder Neoplasms

United States, Korea, Republic of, France, Israel, Spain, Italy, United Kingdom, Belgium, Netherlands, Germany
National Cancer Institute (NCI)

Not yet recruiting

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

Breast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In Situ | Estrogen Receptor-Positive Breast Carcinoma

United States
Fox Chase Cancer Center

Recruiting

Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma

Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma

United States
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Completed

Ten Years Results of a Score System to Address Adjuvant Therapies After Breast Conserving Surgery for Ductal Carcinoma in Situ of the Breast (DCIS)

Carcinoma Breast

Italy
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)

Metastatic Urothelial Carcinoma | Urothelial Neoplasms

Australia, United States, Canada, Chile, France, Israel, Italy, Korea, Republic of, Netherlands, Spain, Taiwan, United Kingdom
The University of Hong Kong
Food and Health Bureau, Hong Kong Government

Active, not recruiting

Hong Kong Breast Cancer Study

Breast Cancer | Ductal Carcinoma In Situ

Hong Kong
Dartmouth-Hitchcock Medical Center
Hologic, Inc.

Completed

Digital Breast Tomosynthesis Versus Contrast Enhanced Magnetic Resonance Imaging (MRI) for Breast Cancer Staging

Invasive Breast Cancer | Ductal Carcinoma In Situ

United States
University of Wisconsin, Madison
National Cancer Institute (NCI); National Center for Advancing Translational...

Completed

Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS

Breast Cancer | Ductal Carcinoma in Situ - Category

United States
Ohio State University Comprehensive Cancer Center
Embr Labs, Inc.

Active, not recruiting

EMBr Wave for the Reduction of Hot Flashes in Women With a History of Breast Cancer

Hot Flashes | Breast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In Situ

United States
Atossa Therapeutics, Inc.

Terminated

A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant (007)

Female Breast Carcinoma | Female Ductal Carcinoma In Situ

United States
Abdelwahab Hashem

Unknown

Bladder Perforation Post-TURBT: Definition, Incidence and Natural HistoryStudy (TURBT-BP)

Trauma | Bladder Cancer | Injuries | Bladder Urothelial Carcinoma | Perforation of Bladder | Recurrence Tumor | Resection Margin | Seeding, Neoplasm

Egypt
Allegheny Singer Research Institute (also known...

Recruiting

EXERT-BCH Exercise Regimen to Improve Muscle Mass After Treatment of Breast Cancer

Breast Cancer | Breast Cancer Female | Breast Carcinoma in Situ

United States
AHS Cancer Control Alberta
Pfizer

Completed

SU011248 for Platinum-Refractory Urothelial Cancer Evaluation Trial (SPRUCE)

Bladder Cancer | Urothelial Cancer | Adult

Canada
University of Chicago
National Cancer Institute (NCI)

Withdrawn

Magnetic Resonance Thermal Image Guided Laser Interstitial Thermal Therapy in Treating Patients With Breast Cancer

Stage IA Breast Cancer | Stage IB Breast Cancer | Ductal Breast Carcinoma in Situ | Invasive Ductal Breast Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ

Breast Ductal Carcinoma In Situ

United States
National Taiwan University Hospital
Mackay Memorial Hospital; Kaohsiung Medical University; Tri-Service General Hospital and other collaborators

Recruiting

Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in Situ

Breast Ductal Carcinoma in Situ

Taiwan
Endo Pharmaceuticals

Terminated

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

Carcinoma in Situ | Transitional Cell Carcinoma | Non-muscle Invasive Bladder Cancer

United States
National Cancer Institute (NCI)

Completed

Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer

Healthy, no Evidence of Disease | Lobular Breast Carcinoma in Situ

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the Breast

Breast Cancer

United States
Yale University
Patient-Centered Outcomes Research Institute

Completed

Comparative Effectiveness of Sentinel Lymph Node Biopsy for Ductal Carcinoma In Situ

Ductal Carcinoma In Situ

United States
Sunnybrook Health Sciences Centre

Terminated

Diagnostic Study of Early Breast Cancer Using Ultrasound

Ductal Carcinoma In-situ

Canada
Windy Hill Medical, Inc.

Unknown

Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS)

Ductal Carcinoma In Situ

United States
National Cancer Institute (NCI)

Completed

A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer

Breast Cancer | Ductal Breast Carcinoma in Situ | Atypical Ductal Breast Hyperplasia | Lobular Breast Carcinoma in Situ

United States
Danish Breast Cancer Cooperative Group
Danish Cancer Society

Active, not recruiting

Hypofractionated Versus Standard Fractionated Whole Breast Irradiation to Node-negative Breast Cancer Patients

Breast Cancer | Carcinoma in Situ of the Breast

Denmark
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Recruiting

A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial Carcinoma of the Bladder (SNUGGLE)

Urinary Bladder Neoplasms

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Biomarkers in Tissue Samples From Patients With Ductal Breast Carcinoma in Situ

Breast Cancer
Clinical Hospital Center Rijeka

Not yet recruiting

The Added Value of Contrast Enhanced Mammography to Standard Mammography in Assessing the Extent of DCIS (CEMinDCIS)

DCIS | Breast Carcinoma in Situ | Calcification

Croatia
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

3D-CRT, Proton, or Brachytherapy APBI in Treating Patients With Invasive and Non-invasive Breast Cancer

Estrogen Receptor Positive | Ductal Breast Carcinoma In Situ | Grade 1 Invasive Breast Carcinoma | Grade 2 Invasive Breast Carcinoma | Grade 3 Invasive Breast Carcinoma | Invasive Ductal and Lobular Carcinoma In Situ | Mucinous Breast Carcinoma | Tubular Breast Carcinoma

United States
Roswell Park Cancer Institute

Recruiting

A Patient Navigation Program for Addressing Disparities in Breast Cancer Care

Breast Carcinoma | Breast Ductal Carcinoma in Situ

United States
National Cancer Institute (NCI)

Not yet recruiting

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

Breast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In Situ | Breast Atypical Hyperplasia

United States
Duke University

Withdrawn

Study to Assess Breast Sensation Before and After Breast Cancer Treatment

Breast Reconstruction | Ductal Carcinoma In-situ

United States
Julie Nangia
Incyte Corporation; Translational Breast Cancer Research Consortium

Recruiting

Ruxolitinib for Premalignant Breast Disease (TBCRC042)

Ductal Carcinoma In Situ | Atypical Ductal Hyperplasia | Atypical Lobular Hyperplasia | Lobular Carcinoma In Situ

United States
MedPacto, Inc.
AstraZeneca

Not yet recruiting

Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition

Urothelial Carcinoma Recurrent | Advanced Urothelial Carcinoma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)

Atypical Hyperplasia of the Breast | Lobular Breast Carcinoma In Situ | Pleomorphic Lobular Breast Carcinoma In Situ

United States, Guam
National Cancer Institute (NCI)

Not yet recruiting

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

Breast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In Situ | Breast Atypical Hyperplasia

United States
University of Southern California

Terminated

Targeted Intra-Operative Radiotherapy for the Management of Ductal Carcinoma In-Situ of the Breast

Breast Cancer

United States

Clinical Trials on Bladder Urothelial Carcinoma In Situ

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uruguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations